SUBSTITUTED INDOLO-PIPERIDINE COMPOUNDS - The present invention relates to substituted indolo-piperidine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted indolo-piperidine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.

ATROPISOMERS OF 2-PURINYL-3-TOLYL-QUINAZOLINONE DERIVATIVES AND METHODS OF USE - The invention provides compounds, compositions and methods to treat certain inflammatory conditions and/or oncology by administering a compound that inhibits PI3K isoforms, particularly the delta isoform. It further provides specific stereoisomers of a compound useful for these methods. In particular, the compound is an optically active atropisomer of 2-((6-amino-9H-purin-9-yl)methyl)-5-methyl-3-o-tolylquinazolin-4(3H)-one.

2010-09-30

20100249156

ANTIVIRAL TOPICAL FORMULATIONS IN THE FORM OF A BIO-ADHESIVE GEL - The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and high resistance to physiological removal mechanisms.

RHO-KINASE INHIBITORS - Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds of the present invention are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.

2010-09-30

20100249160

Cancer Treatment Method - A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

PROCESS FOR THE INTRODUCTION OF HYDROXYETHOXY SIDE CHAIN IN BOSENTAN - The present invention relates to an improved process for the preparation of bosentan. In particular it relates to a process for preparing bosentan substantially free from the dimer impurity of formula (II) and the 6-hydroxy impurity of formula (III). The invention also relates to a pharmaceutical composition comprising bosentan and its use in the treatment of endothelin-receptor mediated disorders.

FORMULATIONS FOR PARENTERAL DELIVERY OF COMPOUNDS AND USES THEREOF - The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

ELLIPTICINE COMPOUNDS FOR TREATING OBESITY - The present invention provides a method of reducing body weight in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I:

2010-09-30

20100249172

9-CHLORO NOSCAPINE AND ITS USE IN TREATING CANCERS, INCLUDING DRUG-RESISTANT CANCERS - 9-Chloro-nos, prodrugs thereof, and pharmaceutically acceptable salts thereof, are disclosed. Pharmaceutical compositions including 9-chloro-nos, and methods of preparation and use thereof are disclosed. 9-Chloro-nos is a noscapine analog that can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers, by binding tubulin and inducing apoptosis selectively in tumor cells (ovarian and T-cell lymphoma) resistant to paclitaxel, vinblastine and teniposide. 9-Chloro-nos can perturb the progression of cell cycle by mitotic arrest, followed by apoptotic cell death associated with increased caspase-3 activation and appearance of TUNEL-positive cells. Thus, 9-chloro-nos is a novel therapeutic agents for a variety of cancers, including ovarian and T-cell lymphoma cancers, even those that have become drug-resistant to currently available chemotherapeutic drugs.

2010-09-30

20100249173

DIHYDROQUINOLINONES AS ECTOPARASITICIDES - Disclosed are uses of dihydroquinolinone derivatives for combating ectoparasites on non-human animals. Example ectoparasites include, for example, representatives of the order acarina, including ticks and mites. Also disclosed are compositions containing dihydroquinolinone derivatives.

HETEROCYCLE AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS - The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.

INDUCTION AND/OR MAINTENANCE OF TUMOR DORMANCY BY DISRUPTION OF UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-INTEGRIN INTERACTION - The present invention relates to a method of inducing cancer cells into dormancy and treating cancer in a subject. This method involves administering to a subject an effective amount of a compound that disrupts interaction between urokinase plasminogen activator receptor and integrin, thereby including cancer cells into dormancy and treating cancer in the subject. Also disclosed is a method of disrupting interaction between integrin and urokinase plasminogen activator receptor on cancer cells. The present invention also relates to a method of screening for compounds effective in inducing tumor dormancy and treating cancer in a subject.

NOVEL DICARBOXYLIC ACID DERIVATIVES AS S1P1 RECEPTOR AGONISTS - The present invention relates to new compounds of formula (I) possessing agonistic activity at sphingosine-1-phosphate (S1P) receptors, their process of preparation and their use as immunosuppressive agents. The invention is also directed to pharmaceutical compositions containing these compounds and use of these compounds for treatment/prevention of immune mediated diseases and conditions or inflammatory diseases and conditions.

2010-09-30

20100249188

PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE - The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.

Hepatitis C Virus Inhibitors - This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

(R)-4-(HETEROARYL) PHENYLETHYL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to a novel class of (R)-4-(heteroaryl)phenylpropionic derivatives of formula (I), useful in the inhibition of the chemotactic activation induced by the fraction C5a of complement. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of autoimmune hemolytic anemia (AIHA), psoriasis, bullous pemphigoid, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.

2010-09-30

20100249199

Hard Surface Treatment Compositions with Improved Mold or Fungi Remediation Properties - Provided are hard surface treatment compositions which provide improved mold and/or fungi remediation properties which compositions are formed from two aqueous mixtures which are admixed immediately prior to use or upon use. The hard surface treatment compositions contain an oxidizing agent, preferably a hypochlorite. In addition to a mold and/or fungi remediation effect, the composition may also be useful in the cleaning treatment and/or disinfection or sanitization treatment of hard surfaces. Methods for the remediation of mold and/or mold spores and/or fungi on surfaces are also disclosed.

AGENT FOR FUNGAL DERMATITIS - The invention relates to a therapeutic agent for fungal dermatitis, containing luliconazole or a pharmaceutically acceptable salt thereof as an active ingredient, and a composition for the treatment of fungal dermatitis, containing luliconazole or lanoconazole in a substantially dissolved state as an active ingredient.

SYNTHESIS OF PYRROLIDINE COMPOUNDS - Provided are methods for the preparation of certain substituted pyrrolidine compounds, forms of (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid hydrochloride, and methods for preparing and using these forms.

2010-09-30

20100249208

Novel Methods and Models for Rapid, Widespread Delivery of Genetic Material to the CNS Using Non-Viral, Cationic Lipid-Mediated Vectors - Provided are safe, non-invasive, non-viral delivery methods for providing a nucleic acid into the neuronal and non-neuronal cells of the central nervous system (CNS) of a subject to protect neuronal and non-neuronal cells from ischemic or traumatic injury, wherein the nucleic acid encodes a therapeutic proteins, specifically providing rapid transient expression and widespread distribution for in vitro or in vivo applications. Further provided are methods for the intrathecal delivery to the cerebrospinal fluid (CSF) of a neuroprotective gene sequence, e.g., a heat shock protein (HSP), complexed with cationic lipid compositions to achieve such delivery, and the complexes used therein.

2010-09-30

20100249209

GENE INVOLVED IN IMMORTALIZATION OF HUMAN CANCER CELL AND USE THEREOF - The present invention provides a gene related to cancer cell immortalization (an immortalization determining gene) and a process that is useful for selective cancer treatment targeting a cancer cell having the gene. The present invention determines an immortalized cancer cell using a polynucleotide having a base sequence of at least 15 bases that specifically hybridizes with a continuous base sequence of at least 15 bases within any one of abase sequences represented by SEQ ID Nos. 1 to 13. In the foregoing process, the polynucleotide is used as a primer or probe for detecting an immortalization determining gene that exhibits high expression specifically in an immortalized cancer cell.

N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs - Provided herein are bicyeMc nucleosides comprising a substituted amino group in the bridge, oligomeric compounds having at least one of these bicyclic nucleosides and methods of using the oligomeric compounds. The bicyclic nucleosides comprising a substituted amino group in the bridge are useful for enhancing properties of oligomeric compounds including nuclease resistance, in certain embodiments, the oligomeric compounds hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

2010-09-30

20100249212

Gene Silencing Using mRNA-cDNA Hybrids - The present invention provides novel compositions and methods for suppressing the expression of a targeted gene using mRNA-cDNA duplexes. The invention further provides novel methods and compositions for generating amplified mRNA-cDNA hybrids, whose quantity is high enough to be used for the invention's gene silencing transfection. This improved RNA-polymerase chain reaction method uses thermocycling steps of promoter-linked double-stranded cDNA or RNA synthesis, in vitro transcription and then reverse transcription to amplify the amount of mRNA-cDNA hybrids up to two thousand folds within one round of the above procedure.

2010-09-30

20100249213

MicroRNA Signatures in Human Ovarian Cancer - The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of ovarian cancer. The invention also provides methods of identifying anti-cancer agents.

2010-09-30

20100249214

MULTIPLEX DICER SUBSTRATE RNA INTERFERENCE MOLECULES HAVING JOINING SEQUENCES - The present invention is based, at least in part, upon the insight that compound DsiRNA agents can be generated using site-specific RNase H-cleavable double stranded nucleic acid double stranded nucleic acid regions to attach, e.g., one DsiRNA moiety to another DsiRNA moiety and/or one DsiRNA moiety to a functional group and/or payload. Because such double stranded nucleic acid joining sequences are site-specifically RNase H-cleavable, the bifunctional molecule is cleaved into DsiRNAs which bear terminal ends that orient dicer cleavage. The detrimental impact of administering a single double stranded nucleic acid RNAi agent of longer than 30-35 nucleotides in length (e.g., provocation of interferon response) can be minimized, as once administered or delivered to a subject or RNase H-containing cell, RNase H cleavage produces a shortened, active DsiRNA agent(s). The invention also provides bifunctional DsiRNA agents that are joined by double stranded DNA extension joining sequences—such bifunctional DsiRNA agents joined by dsDNA sequences do not provoke RNase H cleavage.

2010-09-30

20100249215

Oligomeric Compounds And Compositions For Use In Modulation Of Pri-miRNAs - Compounds, compositions and methods are provided for modulating the levels expression, processing and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided are methods for selectively modulating pri-miRNA levels in a cell. Also provided are methods for identifying oligomeric compounds that result in increase pri-miRNA levels when contacted with a cell.

2010-09-30

20100249216

Method for the production of a cell and/or tissue and/or disease phase specific medicament - The invention relates to a method for the production of a cell and/or tissue and/or disease phase specific medicament against chronic inflammatory diseases. Disease, cell-type, tissue and/or stage specific proteins and nucleic acids are identified with regard to the modified expression pattern and the corresponding nucleic acids are analyzed as possible attack targets for DNAzymes or siRNA. What follows is a design of active specific DNAzymes and siRNA which bind to the target sequence and cleave it such that a medicament against chronic inflammatory diseases and auto-immune diseases is provided.

2010-09-30

20100249217

MODULATORS OF PHARMACOLOGICAL AGENTS - The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

2010-09-30

20100249218

METHOD TO INHIBIT CELL GROWTH USING OLIGONUCLEOTIDES - Described are methods for treating hyperproliferative disorders, including cancers, by administering to the affected mammal (e.g., human) an effective amount of a composition comprising one or more oligonucleotides which share at least 33% but less than 100% nucleotide sequence identity with the human telomere overhang repeat. Methods of treatment or prevention of hyperproliferative diseases or pre-cancerous conditions affecting epithelial cells, such as psoriasis, atopic dermatitis, or hyperprolferative diseases of other epithelia and methods for reducing photoaging, or oxidative stress or for prophylaxis against or reduction in the likelihood of the development of skin cancer, are also disclosed. The compositions and methods are also useful to treating other cancers.

COUMERMYCIN/NOVOBICIN-REGULATED GENE EXPRESSION SYSTEM - A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.

2010-09-30

20100249221

IN VIVO AND EX VIVO GENE TRANSFER INTO RENAL TISSUE USING GUTLESS ADENOVIRUS VECTORS - A method for treating a renal disease in a subject is disclosed. The method includes administering into a kidney of the subject with an effective amount of a gutless adenoviral vector containing a polynucleotide encoding a therapeutic agent. The gutless adenoviral vector contains the nucleotide sequence of SEQ ID NO:13 or SEQ ID NO:15 and expresses the therapeutic agent in a kidney tissue of the subject.

NEW USE FOR CANNABINOID-CONTAINING PLANT EXTRACTS - The present invention relates to the use of cannabinoid-containing plant extracts in the prevention or treatment of diseases or conditions that are alleviated by blockade of one or more types of TRP channel. Preferably the subset of TRP channel that is blockaded is the TRPA channel. More preferably the TRPA channel is the TRPA1 channel. Preferably the diseases or conditions to be prevented or treated include: neuropathic pain, inflammation or vasoconstriction. Alternatively the TRP channel that is blockaded is the TRPM channel. More preferably the TRPM channel is the TRPM8 channel. Preferably the diseases or conditions to be prevented or treated are cancer. More preferably the cancers to be treated include: cancer of the prostate, cancer of the breast, cancer of the colon, cancer of the lung or cancer of the skin. Alternatively the TRP channel that is blockaded is the TRPV channel. More preferably the TRPV channel is the TRPV1 channel. Preferably the diseases or conditions to be prevented or treated include neuropathic pain, inflammation or vasoconstriction.

2010-09-30

20100249224

Methods and compositions for modulating glutamate dehydrogenase - Compositions, compounds, and methods for modulating the activity of glutamate dehydrogenase are disclosed. In addition, compositions, compounds, and methods for regulating insulin secretion and treating hyperinsulism/hyperammonemia and/or diabetes are disclosed.

2010-09-30

20100249225

C-(2-Phenyl-Cyclohexyl)-Methylamine Compounds for the Treatment of Anxiety Disorders - Pharmaceutical formulations of [2-(3-methoxyphenyl)-cyclohexylmethyl]-dimethylamine and the metabolites thereof for treating anxiety, anxiety attacks and disorders as well as depression. Related methods of treating anxiety and anxiety attacks or depression are also provided, including methods of administering the active compounds as adjuvants to an antidepressant.

Compositions Containing Zinc Salts For Coating Medical Articles - The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts and antimicrobial agents in coatings for medical articles. The coatings have an anti-irritant effect and inhibit transmission of infectious disease.

2010-09-30

20100249228

SARMS AND METHOD OF USE THEREOF - This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.

ANTIVIRAL ACTIVITY OF CYCLOPENTENE NITRO-ESTER AND DERIVATIVES - Disclosed is a method of synthesizing new optically pure heterocyclic compounds using Pd(0) catalyzed intramolecular cyclizations. Analogs of cyclopentanes, like isoxazoline-2-oxide and furan, with similar framework to the cyclopentanes act as anti-HIV and anticancer agents which opens a whole new field for application of these compounds. Starting from a meso-diol, optically pure compounds were prepared without utilizing chiral ligands at any stage of the synthesis. The stereochemical outcome of the product (>99% ee) was influenced by desymmetrization catalyzed by

MOSQUITO REPELLENT - The present invention relates to a mosquito repellent comprises at least one or more selected from the group consisting of neric acid and derivatives thereof in an effective amount to repel mosquito.

2010-09-30

20100249233

COMPOUND AND USE THEREOF IN THE TREATMENT OF AMYLOIDOSIS - The present invention relates to compounds of formula (I) for stabilizing the tetrameric form of transthyretin, compounds for use in the treatment or prevention of amyloidosis, and agents and medicaments comprising such compounds.

2010-09-30

20100249234

METHODS OF REDUCING VIRULENCE IN BACTERIA - A method of reducing virulence in a bacterium comprising at least one of a GacS/GacA-type system, a HrpX/HrpY-type system, a T3SS-type system, and a Rsm-type system, the method comprising contacting the bacterium with an effective amount of a phenylpropanoid-type inhibitory compound.

ADHESIVE AND PLASTER - An adhesive comprising a base with tackiness, an oil and ketoprofen, wherein the adhesive contains no L-menthol, the base is composed at least of a tacky composition comprising an elastomer and a tackifier and/or a tacky polymer containing an unsaturated monomer with a total of 5 or more carbon atoms as the monomer unit, the oil is an oil that is compatible with the tacky composition and the tacky polymer, and the oil content is 150-175 parts by weight with respect to 100 parts by weight as the total of the tacky composition and the tacky polymer.

PHARMACEUTICAL COMPOSITIONS COMPRISING SEMICARBAZONES AND THIOSEMICARBAZONES AND METHOD FOR TREATING INFLAMMATORY, PAINFUL AND FEBRILE CONDITIONS AND PREVENTING SIGNS AND SYMPTOMS OF INFLAMMATION - The present patent application refers to pharmaceutical compositions comprising at least a semicarbazone or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof, for the treatment of inflammatory, febrile and painful inflammatory conditions, inflammatory edema and peripheral or central neurophatic painful conditions or prevention of signs and symptoms of inflammation. Claim also pharmaceutical compositions comprising at least a semicarbazone, or a thiosemicarbazone, or a pharmaceutically acceptable salt, hydrated or solvated thereof and a therapeutically effective amount of these compounds, mixed or included in a pharmaceutically acceptable carrier or excipient or a thiosemicarbazone is provided as sustained or controlled release systems for human and veterinary use in solutions or in the solid state.

SYNERGISTIC MIXED POLOXAMER SYSTEMS FOR THE SOLUBILISATION OF DRUGS - Drugs which are difficult to solubilise in water, and especially those which otherwise cause pain on injection, can be readily formulated and typically administered with substantially less pain when solubilised in synergistic, aqueous micellar preparations of poloxamers. Such preparations may also be prepared with less, or without, co-solvents.

2010-09-30

20100249241

N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME - Disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a preparation method thereof and a pharmaceutical composition comprising the same. More specifically, disclosed herein are a novel dicarboxylic acid salt of N,N-dimethylimidodicarbonimidic diamide, a crystalline acid addition salt prepared by allowing N,N-dimethylimidodicarbonimidic diamide to react with a specific dicarboxylic acid, which has improved physical and chemical properties including solubility, stability, non-hygroscopicity and anti-adhesive properties, and low toxicity, and thus is very effective in the prevention and treatment of not only diabetes and its complications in patients with so-called metabolic syndromes, in which diabetes, obesity, hyperlipidemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndromes, etc. appear in combination, but also p53 gene-deficient cancers, muscular pain, muscle cytotoxicity and rhabdomyolysis, as well as a preparation method thereof and a pharmaceutical composition comprising the same.

2010-09-30

20100249242

METHOD OF REDUCING NEURONAL CELL DAMAGE - The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and/or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and/or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.

METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS - The presently claimed and disclosed inventive concept(s) contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These DHE and/or IE and/or EV or salts, esters, ethers or derivatives thereof also are delivered to a measurable extent transepidermally or transdermally. In one of its method aspects, this presently claimed and disclosed inventive concept(s) is directed to a method for treating a patient with a dermatological disease or condition by topically administering to said patient a pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically acceptable topical carrier and an effective dermatological disease, disorder or condition-treating amount of a formulation of DHE and/or IE and/or EV, or salts, esters, ethers, or derivatives thereof. In particular, the presently claimed and disclosed inventive concept(s) is directed to a method of using a composition comprising one or more of DHE and/or IE and/or EV or salts, esters, ethers, or derivatives for treating dermatologic diseases, disorders or conditions, aging effects related to decreasing production of collagen, elastin, or hyaluronic acid, or to hyperpigmentation. The formulations may further contain cinnamaldehyde.

2010-09-30

20100249245

STERILIZING COMPOSITION - Disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant having a cloud point in the range of about 30° C. to 50° C. Also disclosed is a sterilizing composition including (i) at least one mono or dialdehyde; (ii) at least one glycol or polyol or derivative thereof; (iii) a non-ionic first surfactant; and (iv) a second surfactant, wherein the second surfactant is a quaternary ammonium compound. A process for preparing the compositions of the invention is also disclosed. The compositions of the invention are low or substantially non-foaming under high pressure, high temperature conditions, thus allowing maximum benefit from the new, more reliable, generation of automated endoscope reprocessing machines.

2010-09-30

20100249246

Therapeutic Compounds - A (−)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or prodrug thereof, is useful as an anesthetic.

2010-09-30

20100249247

ANTIMICROBIAL COMPOSITIONS - An antimicrobial composition for use as a disinfectant or a preservative. The disinfectant may be used in disinfecting and cleaning surfaces. The preservative is particularly useful in personal care and cosmetic products, and pharmaceuticals. The composition includes a base component and an alkyl mono propylene glycol ether, an alkyl mono glycerol ether, or a combination of these ethers. The base component may be water, alcohol, lotion, cream, shampoo, soap, cosmetic color agent, hair conditioner, lip balm, and face, eye or lip make up, ointment.